Pelvalon Announces New Analysis From The LIFE Pivotal Trial At The 2014 ICS Conference And Unveils The Brand Name For Its Vaginal Bowel Control Therapy
by Traci Bratton
The LIFE study was originally presented at the 2014 AUGS/IUGA Scientific Meeting by Holly E. Richter, Ph.D, M.D., Director of the Division of Urogynecology and Pelvic Reconstructive Surgery at the University of Alabama at Birmingham. At the 1-month primary endpoint, 79% of women in the intent-to-treat cohort and 86% of the per protocol cohort experienced treatment success, and zero device-related serious adverse events were reported.